Pol Merkur Lekarski. 2025;53(2):203-211. doi: 10.36740/Merkur202502108.
ABSTRACT
OBJECTIVE: Aim: This preclinical study was oriented towards evaluating the efficiency of newly developed antibiotics against a selection of multi-drug-resistant Staphylococcus aureus strains, with the broader aim of finding a potent candidate to counteract the increasing resistance issue.
PATIENTS AND METHODS: Materials and Methods: The study utilized four distinct strains of multi-drug-resistant Staphylococcus aureus (SA-1 to SA-4) and three novel antibiotics (NA-1 to NA-3) under controlled laboratory conditions. The bacterial strains were cultured in vitro, and a series of tests including drug susceptibility testing and the determination of minimum inhibitory concentrations (MIC) were conducted. Statistical analysis was carried out using two-way ANOVA and Bonferroni post-hoc tests to analyze the significance of the observed results.
RESULTS: Results: Our data showcased variations in the growth characteristics and resistance profiles of the different strains, helping in identifying the most potent antibiotic among the tested compounds. Notably, antibiotic NA-1 manifested the lowest MIC values against the strains SA-1 and SA-3, indicating a higher potency (p < 0.01). Moreover, NA-1 exhibited significantly lower MIC₅₀ and MIC₉₀ values (0.56 μg/mL and 0.95 μg/mL, respectively), suggesting that it had the best inhibitory power amongst the antibiotics tested against a majority of the strains (p < 0.05).
CONCLUSION: Conclusions: The findings from this preclinical in-vitro study accentuate the potential of novel antibiotic NA-1 as a promising candidate in combatting multidrug- resistant Staphylococcus aureus strains. However, further research, including in-vivo studies, is requisite to substantiate the efficacy of this antibiotic in a clinical setting.
PMID:40322803 | DOI:10.36740/Merkur202502108